Floatz logo

Tabelecleucel

EBV-induced Lymphomas

Atara BiotherapeuticsCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the EBV-induced Lymphomas cohort.

Asset / SponsorPhaseRating
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes
Atara Biotherapeutics
Phase 1/2CCC
Ebv-Specific T Cells: B
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Avelumab
Yonsei University
Phase 2CCC
Ebv Mrna Vaccine
Sun Yat-sen University
Phase 1CC
qs-21
Ohio State University Comprehensive Cancer Center
Phase 1NR

Same molecule, other indications

Tabelecleucel is also rated in:

disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
66 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
BB
Indicative ·
66 / 100
View asset →
Solid Organ Transplant ComplicationsDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →